Immunotherapy, a rapidly evolving field in cancer treatment, capitalizes on the body's innate immune system to combat malignancies. It has revolutionized the medical landscape, offering new hope to patients with various types of cancers. This article aims to provide a comprehensive understanding of the fundamental principles of immunotherapy.
Immunotherapy works by stimulating or restoring the immune system's ability to fight off cancer. It uses substances produced by the body or in a laboratory to bolster or manipulate immune responses. The two main types of immunotherapy include active and passive. Active immunotherapy stimulates the immune system to attack cancer cells, while passive immunotherapy involves the administration of immune components, such as antibodies.
Immunotherapy encompasses a broad range of treatments including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapy. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. Immune checkpoint inhibitors block immune checkpoints, enhancing immune responses against cancer cells. Cancer vaccines are substances introduced into the body to provoke an immune response against certain diseases. Adoptive cell therapy involves the modification of a patient's T cells to enhance their ability to fight cancer.
Despite the significant advances in immunotherapy, challenges persist. These include side effects, the unpredictability of responses, and the high cost of treatment. Future research is focusing on identifying biomarkers to predict response, refining treatment combinations, and minimizing toxicity.
Immunotherapy represents a paradigm shift in cancer treatment. While challenges exist, its potential to offer a therapeutic advantage over traditional treatments is significant. As research continues to unravel the complexities of the immune system, we can anticipate further advancements in this promising field.
1.
Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC
2.
Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy
3.
Study: Elinzanetant cuts vasomotor symptoms in women with breast cancer on endocrine therapy
4.
Biocomputer From Human Neurons Plays Doom, Raises Ethics
5.
AI is useful in low-resource areas for triaging breast masses.
1.
Navigating the Complexity of Peritoneal Carcinomatosis: A Guide for Patients and Caregivers
2.
Clinical Perspectives in Oncology for Better Care
3.
The Different Types of Cysts and Why They Occur: Insights from a Dermatologist
4.
Emerging Therapies Using Immune-Engineered Cancer Eradication Platforms
5.
Radiomics-Based Prediction of Treatment Response in Cancer
1.
International Conference on Oncology, Cardiology and Critical Care Policy
2.
International Conference on Innovations in Critical Care for Oncology and Cardiology
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Cancer Nursing and Hematology Support
1.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Navigating the Complexities of Ph Negative ALL - Part XIII
5.
Innovations in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation